Search

for
Search:

GlossaryMEK inhibitors

block enzymes involved in cell growth signaling pathways

MEK inhibitors, also known as MEKis or MEK1/2 inhibitors, are a class of drugs that block the activity of the MEK enzymes (MEK1 and MEK2), which are part of the MAPK/ERK signaling pathway. This pathway is crucial for cell division and survival, and its dysregulation is often implicated in various cancers. By inhibiting MEK, these drugs can help to slow down or stop the growth of cancer cells.

Related Terms

Sort by

Research

30 / 518 results

research Melanotic pigmentation in excisional scar of melanoma patient who received BRAF and MEK inhibitors

1 citations , August 2018 in “Journal of The American Academy of Dermatology”

Patients with melanoma who saw dermatologists and were from higher-income areas were more likely to have follow-up visits, which was linked to lower mortality.

research 422 Human hair follicles express PD-L1, whose expression is down-regulated by EGFR and MEK inhibitors ex vivo. A potential mechanism for EGFR inhibitor induced sterile folliculitis

September 2019 in “Journal of Investigative Dermatology”

EGFR and MEK inhibitors reduce PD-L1 in hair follicles, possibly causing inflammation.

research 696 MEK and BRAF inhibitors augment the production and accumulation of sebum in hamster sebocytes

April 2016 in “Journal of Investigative Dermatology”

MEK and BRAF inhibitors increase sebum production and accumulation, which could cause acne-like side effects.

research 861 EGFR/MEK inhibitor therapy induces partial hair follicle immune privilege collapse in vivo and ex vivo

July 2022 in “Journal of Investigative Dermatology”

research IL-36γ drives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes

32 citations , December 2019 in “The Journal of clinical investigation/The journal of clinical investigation”

A protein called IL-36γ causes skin side effects from certain cancer treatments when combined with a common skin bacteria.

research Cutaneous Toxicities of MEK Inhibitor Use in Children: A Comparison of Binimetinib and Selumetinib

3 citations , November 2024 in “Pediatric Dermatology”

Selumetinib causes fewer and less severe skin issues in children than binimetinib.

research 645 MIG6 is MEK-regulated and affects EGF-induced migration in mutant NRAS melanoma

April 2016 in “Journal of Investigative Dermatology”

Decreasing MIG6 can increase the movement and invasiveness of MEK-inhibited mutant NRAS melanoma, particularly when stimulated by EGF.

research Continuous MEK inhibition by AZD6244 (ARRY-142886) results in exhaustion of the cutaneous keratinocytic stem cell pool and resembles senescence driven skin aging

2 citations , May 2008 in “Journal of Clinical Oncology”

AZD6244 treatment causes skin aging effects by depleting skin stem cells.

research Cutaneous toxicities of new treatments for melanoma

25 citations , May 2018 in “Clinical & Translational Oncology”

New melanoma treatments can cause skin side effects, including skin cancer and rashes, but combining treatments may reduce these risks.

research Dermatologic adverse events associated with chemotherapy and targeted anticancer therapy

4 citations , January 2016 in “Dermatology Review”

Cancer treatments often cause skin, nail, and hair problems.

research When bugs and drugs conspire: driving acneiform skin toxicity

1 citations , February 2020 in “The Journal of clinical investigation/The journal of clinical investigation”

Certain cancer drugs interact with skin bacteria to cause acne-like rashes.

research Adverse Hair Reactions to New Targeted Therapies for Cancer

1 citations , March 2019 in “Actas Dermo-Sifiliográficas”

New cancer treatments are less harmful to hair but can still cause hair loss, color, shape, and growth changes.

research 642 Uncovering the role of UV exposure history and genetics in determining skin sun damage

1 citations , April 2016 in “Journal of Investigative Dermatology”

UV photography can help identify people at higher risk for skin cancer, and male pattern baldness at age 45 is linked to a higher risk of certain skin cancers.

research Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies

June 2023 in “Cancers”

Modern skin cancer treatments can cause skin side effects and hair loss, affecting patients' quality of life.

research Dermatologic Side Effects of Systemic Targeted Anticancer Therapy

January 2018 in “Springer eBooks”

Cancer treatments targeting specific cells often cause skin, hair, and nail problems, affecting patients' lives and requiring careful management.

research Cutaneous Drug Eruptions Associated with the Use of New Oncological Drugs

29 citations , January 2012 in “Chemical immunology/Fortschritte der Allergielehre/Progress in allergy/Chemical immunology and allergy”

New cancer drugs often cause skin and nail problems.

research Sorafenib-induced eruption resembling pityriasis rubra pilaris

21 citations , July 2011 in “Journal of the American Academy of Dermatology”

A man developed a rash similar to pityriasis rubra pilaris after starting sorafenib for cancer, possibly due to the drug's effect on skin cells.

research Cutaneous adverse effects of targeted therapies

149 citations , January 2015 in “Journal of the American Academy of Dermatology”

Targeted cancer therapies often cause skin side effects, needing dermatologist care.

research Progesterone promotes the survival of newborn neurons in the dentate gyrus of adult male mice

85 citations , May 2009 in “Hippocampus”

Progesterone helps adult male mice grow more neurons and improves memory.

research Management of Dermatologic Toxicities

12 citations , May 2015 in “Journal of the National Comprehensive Cancer Network”

Doctors should actively prevent and treat skin side effects in cancer patients to keep them on the best medication and reduce discomfort.

research Progesterone Promotes the Survival of Newborn Neurons in the Dentate Gyrus of Adult Male Mice

January 2010 in “Acta Universitatis Medicinalis Nanjing”

Progesterone helps adult male mice's brain cells survive and improves learning and memory.

research RASopathic Skin Eruptions during Vemurafenib Therapy

82 citations , March 2013 in “PLoS ONE”

Vemurafenib causes skin side effects similar to RASopathies, requiring regular skin checks and UVA protection.

research 329 Mechanisms of Cutaneous Adverse Events during Targeted Cancer Therapy

November 2022 in “The journal of investigative dermatology/Journal of investigative dermatology”

Targeted cancer therapies can cause skin side effects, but activating SOS in the skin may help reduce them.

research Targeted therapy in melanoma

21 citations , February 2013 in “Clinics in Dermatology”

New treatments for advanced skin cancer are improving patient outcomes, but drug resistance and finding the right treatment combinations are still big challenges.

research The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?

54 citations , September 2012 in “Acta ophthalmologica”

Cancer treatments can cause various eye problems, so eye doctors should know how to diagnose and treat these early.

research Multimodal therapeutic approach for a severe case of kaposiform lymphangiomatosis from procedural interventions to targeted therapies

1 citations , May 2024 in “Pediatric Blood & Cancer”

Trametinib can effectively treat severe kaposiform lymphangiomatosis when other treatments fail.

research Self‐Assembled Peptide Hydrogels Loaded with Umbilical Cord‐Derived Mesenchymal Stem Cells Repairing Injured Endometrium and Restoring Fertility

11 citations , August 2024 in “Advanced Healthcare Materials”

A new hydrogel with stem cells can repair damaged uterine lining and improve fertility.

research Biological therapy in the treatment of melanoma

3 citations , October 2018 in “Journal of Mind and Medical Sciences”

Biological therapy boosts the immune system to effectively fight melanoma.

The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: The Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma

research The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: the Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma

6 citations , April 2013 in “Current Dermatology Reports”

Dermatologists are crucial for managing skin side effects in metastatic melanoma patients using vemurafenib and ipilimumab.

research Unique Cutaneous Reaction to Second- and Third-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia

32 citations , September 2015 in “Dermatology”

Certain leukemia drugs can cause severe skin reactions that may require stopping treatment.